Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.46 |
| ▸ | HTR3B | O95264 | 1/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.46 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | MIF | P14174 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | LTA | P01374 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11574824 | 0.84 | TDP1 (0.42) | TDP1MAPK1CYP3A4P2RY6MIF | |
| SCHEMBL3036837 | 0.81 | P2RY6 (0.45) | TDP1CYP3A4P2RY6MIFTRPA1 | |
| SCHEMBL1052023 | 0.81 | TDP1 (0.63) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29976261 | 0.81 | TDP1 (0.63) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14926683 | 0.81 | HTR3E (0.53) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL29794124 | 0.80 | MAPK1 (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL60373 | 0.80 | MAPK1 (0.68) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14926708 | 0.79 | HTR3E (0.52) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL484205 | 0.78 | CYP3A4 (0.60) | TDP1MAPK1CYP3A4P2RY6MIF | |
| SCHEMBL17289576 | 0.78 | TDP1 (0.44) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2020-12-08 | — | — | US | disclosed |
| EP-3559005-A1 | THIENOPYRROLE DERIVATIVES FOR USE IN TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Biotheryx Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-3327013-B1 | 5-SUBSTITUTED ISOINDOLINE COMPOUNDS | CELGENE CORP (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-2560978-B1 | INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS | MARS INC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-0876354-A1 | 2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-11-11 | — | — | EP | disclosed |
| US-5821372-A | USEFUL FOR INCREASING BLOOD SERUM HIGH DENSITY LIPOPROTEIN LEVELS(HDL) | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-10-13 | — | — | US | disclosed |
| WO-1997019931-A1 | 2-(SUBSTITUTED SULFANYL)-3,5-DIHYDRO-IMIDAZOL-4-ONE DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-05 | — | — | WO | disclosed |
| WO-1997019932-A1 | 2-THIOXO-IMIDAZOLIDIN-4-ONE DERIVATIVES AND THEIR USE FOR INCREASING HDL CHOLESTEROL CONCENTRATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-05 | — | — | WO | disclosed |
| US-5599829-A | FOR INCREASED HIGH DENSITY LIPOPROTEIN LEVELS IN BLOOD | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-02-04 | — | — | US | disclosed |
| US-5554607-A | INCREASING HDL CHOLESTEROL | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-09-10 | — | — | US | disclosed |
| US-5393883-A | Ribonucleotide reductase inhibitors | BURROUGHS WELLCOME CO. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5175165-A | Acyclovir and a thiocarbonohydrazone ribonucleotide reductase inhibitor for treatment of herpes virus | BURROUGHS WELLCOME CO. (US) | 1992-12-29 | — | — | US | disclosed |
| EP-0349243-B1 | ANTIVIRAL COMBINATIONS AND COMPOUNDS THEREFOR | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-04-01 | — | — | EP | disclosed |
| EP-0349243-A2 | Antiviral combinations and compounds therefor | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345714-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | HTR3E 4113/4885HTR3B 3126/4885HTR3A 1933/4885 |
| US-20210139500-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, CKS2 | HTR3E 4181/4885HTR3B 3257/4885HTR3A 2140/4885 |
| US-10336771-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | HTR3E 4113/4885HTR3B 3126/4885HTR3A 1933/4885 |
| US-10857155-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | HTR3E 4073/4885HTR3B 3176/4885HTR3A 3284/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | HTR3E 4113/4885HTR3B 3126/4885HTR3A 1933/4885 |
| US-10406165-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | GSPT1, GSPT2, GGT1 | HTR3E 4073/4885HTR3B 3176/4885HTR3A 3284/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | HTR3E 4113/4885HTR3B 3126/4885HTR3A 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.